CASE REPORT

Juvenile interleukin-36 receptor antagonist deficiency (DITRA) with c.80T>C (p.Leu27Pro) mutation successfully treated with etanercept and acitretin

Edwin Cuperus, MD,a Rosanne Koevoets, MD, PhD,b Jasper J. van der Smagt, MD, c Johan Toonstra, MD, PhD,b Marlies de Graaf, MD, PhD,b Joost Frenkel, MD, PhD, d and Suzanne G. M. A. Pasmans, MD, PhD,a,b Rotterdam and Utrecht, The Netherlands

Key words: deficiency of interleukin-36 receptor antagonist; etanercept; pustular psoriasis; treatment.

INTRODUCTION

General pustular psoriasis (GPP) is a rare form of psoriasis and is clinically characterized by widespread eruptions of sterile pustules and bright erythematous skin accompanied by periods of fever, chills, rigors, neutrophilia, and elevated serum C-reactive protein.1 Acrodermatitis of Hallopeau, palmoplantar psoriasis pustulosis, and annular pustular psoriasis may be variations of this GPP.2 In 2011, Marrakchi et al3 reported a subgroup of GPP patients with a specific genetic defect: a deficiency of interleukin-36 receptor antagonist (DITRA). We report a case of juvenile DITRA successfully treated with acitretin in combination with etanercept.

CASE REPORT

We present a case of a child that was referred to us at the age of 2 months. She was the first child of 2 consanguineous Moroccan parents. No complications were reported during pregnancy or delivery (gestational age at delivery was 41 weeks and 6 days). There was no family history of psoriasis. The first week postpartum, multiple pustules appeared in the perioral and diaper area. At the age of 7 weeks, an erythroderma developed with maceration in the folds (Fig 1, A). Zinc level, complement-5, and lymphocyte subsets were normal. Chest radiograph was normal, and no hair or nail abnormalities were found. A diagnosis of juvenile seborrheic dermatitis was made at that time, and she was treated with topical steroids with a good response.

In the following months, she had recurrent episodes of erythroderma, fever, vomiting, failure to thrive, leukocytosis, and elevated acute-phase protein levels. At 6 months, she was admitted to the hospital for diarrhea and imminent dehydration. Palmoplantar confluent pustules were seen, suspect for pediatric acral pustulosis or pustular psoriasis. Topical steroids were sufficient to stabilize the disease. The next months were complicated by dehydration caused by a norovirus infection (age 8 months), and adrenocortical insufficiency (age 10 months) possibly caused by the topical steroids. At 14 months, little improvement was seen using coal tar 5% in vaseline-lanette cream and mometasone ointment 2 to 3 times per week.

From the Department of Dermatology, Sophia Children’s Hospital, Erasmus MC University Medical Centre Rotterdam; the Department of Dermatology, University Medical Centre, Utrecht; and the Departments of Clinical Genetics and Pediatrics, Wilhelmina’s Children Hospital, University Medical Centre, Utrecht.

Funding sources: None.

Conflicts of interest: None declared.

Correspondence to: Suzanne G. M. A. Pasmans, MD, PhD, Department of (Pediatric) Dermatology, Sophia’s Children Hospital, Erasmus MC University Medical Centre, Rotterdam.

Abbreviations used:
DITRA: deficiency of interleukin-36 receptor antagonist
GPP: generalized pustular psoriasis
IL36RN: interleukin-36 receptor gene
OMIM: online Mendelian inheritance in man
PASI: psoriasis activity and severity index

JAAD Case Reports 2018;4:192-5. 2352-5126 © 2017 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.jdcr.2017.08.019
At 17 months, the clinical picture changed with generalized pustules including scalp, palms, and soles. A skin biopsy found parakeratosis and pustules containing neutrophils, supporting a diagnosis of psoriasis pustulosa. Around this time, the first publications of DITRA (online Mendelian inheritance in man [OMIM] #614204) appeared and Sanger sequence analysis of the \textit{IL36RN} gene found a homozygous mutation, c.80T>C (p.Leu27Pro), confirming the diagnosis of DITRA at 18 months of age.

During the course of her disease, multiple systemic therapies were administered with different outcomes as illustrated by the PASI (Psoriasis Activation and Severity Index) scores (mean, 24.0; range, 0.7-57.6) assessed at different time points and based on clinical presentation (Fig 2). Cyclosporin (4 mg/kg/d for 2 months) induced increase of erythema and pustules. With anakinra (5 mg/kg/d for 6 days) the pustules initially disappeared, but within 6 days there was a flare and persistent erythema. Acitretin was given for 2 years and 8 months at an initial dose scheme according to Chao et al (initially 1 mg/kg/d) and showed initially a good response with a PASI score of 0.7. During the following relapses and remissions, the acitretin dose varied between 0.4 mg/kg/d and 1 mg/kg/d. Etanercept (12.5 mg/wk) was added to acitretin with a good response for 6 months, even reaching a PASI score of 0.0 after the fifth injection of etanercept (see Fig 2). After 6 months, good improvement is seen with acitretin, 15 mg/d, and etanercept 12.5 mg/wk (Fig 1, B). No side effects were noticed by clinicians or reported by the parents.

**DISCUSSION**

Deficiency of DITRA is a subgroup of GPP patients with a specific monogenetic defect that is difficult to treat. Recommendations for first- and second-line therapies in GPP patients are made in cooperation with the Board of the National Psoriasis Foundation. In children, first-line therapies include acitretin, cyclosporin, methotrexate, and etanercept, and second line therapies include adalimumab, infliximab, and ultraviolet B phototherapy. There are no guidelines for the treatment of DITRA, and most cases presented in literature with therapeutic outcomes are derived from case reports and case series, reflecting the extreme rarity of the disorder. Follow-up periods in these patients, when mentioned, have been limited. This case illustrates a patient with juvenile DITRA, showing response to different systemic therapies and reporting an initially successful treatment with acitretin and a good response to acitretin combined with etanercept after a relapse.

Since the discovery of DITRA in 2011, fewer than 15 juvenile patients with DITRA and corresponding therapeutic outcomes were documented. The mutation c.80T>C/p.Leu27Pro in our case is identical to that originally described by Marrakchi et al in 2011 and was only described twice after (Table I). One described by Rossi-Semerano et al was successfully treated with anakinra (2-4 mg/kg/d for 2 months). However, in the case described by Carapito et al, treatment with anakinra (5 mg/kg/d for 3 months) was not successful. In our patient, anakinra in a similar dose (100 mg/d), had to be stopped after 6 days because of a flare of the disease. Recent treatment of juvenile DITRA (C115+6T>C/p.Arg10ArgfsX1) with tumor necrosis factor-\alpha blockers (infliximab) was reported to be successful and unsuccessful. Similar treatments in patients with identical mutations result in different outcomes, illustrating the complexity of the disease and its treatment. A recent publication showed a possible correlation between disease severity in DITRA,
mutation of the IL36RN gene, and IL36RN protein expression. Null mutations with complete absence of IL36RN antagonist (eg, c.80T>C/p.Leu27Pro) were associated with severe clinical phenotypes compared with mutations with decreased or unchanged protein expression. As mentioned, little is known about the treatment in DITRA, and treatment response is difficult to monitor, because DITRA by its nature is characterized by remissions and flares. DITRA patients can lose response to therapy, even after prolonged use, as is seen in our case with acitretin as monotherapy. Although the therapy with acitretin and etanercept looks promising within 6 months, diminished therapy effect is still possible.

**CONCLUSION**

DITRA is a recently described variation of GPP. Little is known about treatment regimes. Our case of juvenile DITRA describes a good effect of acitretin in combination with etanercept for 6 months. Further research is necessary about optimal treatment for DITRA in relation to mutation status.

---

**Table I. Therapy outcomes in juvenile patients with c.80T>C/p.Leu27Pro mutation**

| Study        | Age | Sex | Final treatment | Duration | Response | Outcome details                     | Previous treatment(s)       |
|--------------|-----|-----|-----------------|----------|----------|-------------------------------------|-----------------------------|
| 1 Carapito et al⁶ | 8 mo | M   | Anakinra        | 3 mo     | None     | —                                   | Canakinumab                 |
| 2 Rossi-Semerano et al⁷ | 6 wk | M   | Anakinra        | 2 mo     | Good     | Recovery after 8 days, no flares after 2 months | —                           |
| 3 Current case | 3 y  | F   | Acitretin + etanercept | 6 mo     | Good     | —                                   | Cyclosporin, topical steroids, anakinra, acitretin |

---

**Fig 2.** PASI scores of our patient during different treatments.
REFERENCES
1. Iizuka H, Takahashi H, Ishida-Yamamoto A. Pathophysiology of generalized pustular psoriasis. Arch Dermatol Res. 2003;295(Suppl 1):S55-S59.
2. Setta-Kaffetzi N, Navarini AA, Patel VM, et al. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J Invest Dermatol. 2013;133:1366-1369.
3. Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365:620-628.
4. Chao PH, Cheng YW, Chung MY. Generalized pustular psoriasis in a 6-week-old infant. Pediatr Dermatol. 2009;26:352-354.
5. Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67:279-288.
6. Carapito R, Isidor B, Guerouaz N, et al. Homozygous IL36RN mutation and NSD1 duplication in a patient with severe pustular psoriasis and symptoms unrelated to deficiency of interleukin-36 receptor antagonist. Br J Dermatol. 2015;172:302-305.
7. Rossi-Semerano L, Piram M, Chiaverini C, et al. First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra. Pediatrics. 2013;132:e1043-e1047.
8. Pan J, Qiu L, Xiao T, Chen HD. Juvenile generalized psoriasis with IL36RN mutation treated with short-term infliximab. Dermatol Ther. 2016;29:164-167.
9. Song HS, Yun SJ, Park S, et al. Gene mutation analysis in a korean patient with early-onset and recalcitrant generalized pustular psoriasis. Ann Dermatol. 2014;26:424-425.
10. Tauber M, Bal E, Pei XY, et al. IL36RN mutations affect protein expression and function: a basis for genotype-phenotype correlation in pustular diseases. J Invest Dermatol. 2016;136(9):1811-1819.